Taiwan Universe BioMedicine (TaiU), a startup spun off from the National Health Research Institutes (NHRI), has completed a NT$60 million (approximately US$2 million) seed funding round led by Mosaic Seed Fund, with matching investment from the National Development Fund. The funds will accelerate development of its bivalent enterovirus vaccine and seasonal influenza VLP vaccine toward clinical trials, with plans to submit an IND application in 2026 and list on the emerging stock market in 2028.
Related articles
ASSA ABLOY acquires PACLOCK in the US
September 16, 2026
MySize Announces $2.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
September 16, 2026
Xpansiv to Acquire Formbay, Australia's AI-Enabled Renewable Energy Certificate and Compliance Technology Platform
September 16, 2026
Generated by Olivia 6